252 related articles for article (PubMed ID: 22851637)
1. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
[TBL] [Abstract][Full Text] [Related]
2. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
3. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin Receptor Antagonists for Imaging and Therapy.
Fani M; Nicolas GP; Wild D
J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
[TBL] [Abstract][Full Text] [Related]
5. Design and development of the theranostic pair
Mansi R; Fani M
J Labelled Comp Radiopharm; 2019 Aug; 62(10):635-645. PubMed ID: 31112618
[TBL] [Abstract][Full Text] [Related]
6. Safety, Biodistribution, and Radiation Dosimetry of
Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
[TBL] [Abstract][Full Text] [Related]
7. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
10. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA
J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
Cescato R; Waser B; Fani M; Reubi JC
J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
[TBL] [Abstract][Full Text] [Related]
12. Head-to-Head Comparison of
Lin Z; Zhu W; Zhang J; Miao W; Yao S; Huo L
J Nucl Med; 2023 Sep; 64(9):1406-1411. PubMed ID: 37474267
[TBL] [Abstract][Full Text] [Related]
13. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography.
Dude I; Zhang Z; Rousseau J; Hundal-Jabal N; Colpo N; Merkens H; Lin KS; Bénard F
EJNMMI Radiopharm Chem; 2017; 2(1):4. PubMed ID: 29503845
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
18. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
